Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells

Gynecologic Oncology

Volumn 124, Issue 3, 2012, Pages 598-605

  Meng, Erhong ^a   Taylor, Brandon ^a   Ray, Anasuya ^a   Shevde, Lalita A ^a   Rocconi, Rodney P ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

BIBR1532; Ovarian cancer; Spheroid forming cells; Telomerase activity

Indexed keywords

ANTINEOPLASTIC AGENT; BIBR 1532; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TELOMERASE ACTIVITY; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TOPOTECAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; SPHEROID FORMING CELL;

AMINOBENZOIC ACIDS; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; HUMANS; NAPHTHALENES; OVARIAN NEOPLASMS; SPHEROIDS, CELLULAR; TELOMERASE;

EID: 84856692785     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.11.018     Document Type: Article

References (18)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J Clin 60 5 Sep.-Oct. 2010 277 300
2. A.B. Alvero, R. Chen, H.H. Fu, M. Montagna, P.E. Schwartz, and T. Rutherford Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance Cell Cycle 8 1 Jan. 1 2009 158 166
3. C.T. Jordan, M.L. Guzman, and M. Noble Cancer stem cells N Engl J Med 355 12 Sep. 21 2006 1253 1261
4. S. Zhang, C. Balch, M.W. Chan, H.C. Lai, D. Matei, and J.M. Schilder Identification and characterization of ovarian cancer-initiating cells from primary human tumors Cancer Res 68 11 Jun 1 2008 4311 4320
5. G. Dontu, M. Al-Hajj, W.M. Abdallah, M.F. Clarke, and M.S. Wicha Stem cells in normal breast development and breast cancer Cell Prolif 36 Suppl. 1 Oct. 2003 59 72
6. C.O. Marian, S.K. Cho, B.M. McEllin, E.A. Maher, K.J. Hatanpaa, and C.J. Madden The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth Clin Cancer Res 16 1 Jan. 1 2010 154 163
7. A. Shervington, C. Lu, R. Patel, and L. Shervington Telomerase downregulation in cancer brain stem cell Mol Cell Biochem 331 1-2 Nov. 2009 153 159
8. R.J. Ward, and C. Autexier Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment Mol Pharmacol 68 3 Sep. 2005 779 786
9. J. Lubin, J. Markowska, A. Markowska, J. Stanislawiak, and T. Lukaszewski Activity of telomerase in ovarian cancer cells. Clinical implications Clin Exp Obstet Gynecol 36 2 2009 91 96
10. B. Ozmen, C.I. Duvan, G. Gumus, M. Sonmezer, M. Gungor, and F. Ortac The role of telomerase activity in predicting early recurrence of epithelial ovarian cancer after first-line chemotherapy: a prospective clinical study Eur J Gynaecol Oncol 30 3 2009 303 308
11. Y. Luo, Y. Yi, and Z. Yao Growth arrest in ovarian cancer cells by hTERT inhibition short-hairpin RNA targeting human telomerase reverse transcriptase induces immediate growth inhibition but not necessarily induces apoptosis in ovarian cancer cells Cancer Invest 27 10 2009 960 970
12. D. Parsch, U. Brassat, T.H. Brummendorf, and J. Fellenberg Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines Cancer Invest 26 6 2008 590 596
13. H. El Daly, and U.M. Martens Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532) Methods Mol Biol 405 2007 47 60
14. S. Mueller, U. Hartmann, F. Mayer, S. Balabanov, J.T. Hartmann, and T.H. Brummendorf Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors Invest New Drugs 25 6 2007 519 524
15. N.W. Kim, M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, and P.L. Ho Specific association of human telomerase activity with immortal cells and cancer Science 266 5193 1994 2011 2015
16. T.C. Chou, and P. Talalay Analysis of combined drug effects: a new look at a very old problem Trends Pharmacol Sci 4 1983 450 454
17. E. Pascolo, C. Wenz, J. Lingner, N. Hauel, H. Priepke, and I. Kauffmann Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleoside drug candidate J Biol Chem 277 2002 15566 15572
18. H. El-Daly, M. Kull, S. Zimmermann, M. Pantic, C.F. Waller, and U.M. Martens Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532 Blood 105 4 Feb. 15 2005 1742 1749